Improving the efficacy of antibody-based cancer therapies

• Published in: Nature reviews. Cancer Vol. 1; no. 2; pp. 118 - 129
• Main Author: Carter, Paul
• Format: Journal Article
• Language: English
• Published: England Nature Publishing Group 01.11.2001
• Subjects: Animals; Antibodies; Antibodies - immunology; Antibodies - therapeutic use; Antibodies, Bispecific - therapeutic use; Antibodies, Monoclonal - immunology; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm - immunology; Antibodies, Neoplasm - therapeutic use; Antibody-Dependent Cell Cytotoxicity; Antigens, Neoplasm - immunology; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Avastin; Cancer; Care and treatment; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cytokines - administration & dosage; Cytokines - therapeutic use; Drug Delivery Systems; Health aspects; Herceptin; Humans; Immunization, Passive; Immunoconjugates - therapeutic use; Immunotherapy - methods; Immunotoxins - therapeutic use; Liposomes; Methods; Mice; Neoplasm Proteins - antagonists & inhibitors; Neoplasm Proteins - immunology; Neoplasm, Residual; Neoplasms - drug therapy; Neoplasms - immunology; Neoplasms - pathology; Neoplasms - radiotherapy; Neoplasms - therapy; Neovascularization, Pathologic - immunology; Neovascularization, Pathologic - therapy; Prodrugs - administration & dosage; Protein Engineering; Radioimmunotherapy; Recombinant Fusion Proteins - immunology; Recombinant Fusion Proteins - therapeutic use; Rituxan; Rituximab; Trastuzumab; Treatment Outcome; vascular endothelial growth factor; Viral antibodies; Xenograft Model Antitumor Assays; United States
• ISSN: 1474-175X; 1474-1768
• DOI: 10.1038/35101072

A quarter of a century after their advent, monoclonal antibodies have become the most rapidly expanding class of pharmaceuticals for treating a wide variety of human diseases, including cancer. Although antibodies have yet to achieve the ultimate goal of curing cancer, many innovative approaches stand poised to improve the efficacy of antibody-based therapies.